# Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome

> **NCT00077116** · PHASE2 · COMPLETED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 31 (actual)

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** busulfan
- **DRUG:** cyclophosphamide
- **DRUG:** cytarabine
- **DRUG:** gemtuzumab ozogamicin
- **DRUG:** idarubicin
- **PROCEDURE:** allogeneic bone marrow transplantation
- **PROCEDURE:** peripheral blood stem cell transplantation
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00077116
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** 2006-11
- **Final completion:** —
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2012-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00077116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00077116, "Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00077116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*